Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

VitaNova Life Sciences (YJGJ) Change in Accured Expenses (2019 - 2026)

VitaNova Life Sciences (YJGJ) has disclosed Change in Accured Expenses for 7 consecutive years, with $8242.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses fell 36.33% year-over-year to $8242.0, compared with a TTM value of -$3043.0 through Oct 2025, down 119.09%, and an annual FY2025 reading of -$5190.0, down 162.52% over the prior year.
  • Change in Accured Expenses was $8242.0 for Q4 2025 at VitaNova Life Sciences, up from $406.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $25563.0 in Q2 2021 and bottomed at -$14185.0 in Q2 2025.
  • Average Change in Accured Expenses over 5 years is $2589.4, with a median of $2297.0 recorded in 2023.
  • The sharpest move saw Change in Accured Expenses plummeted 1319.65% in 2021, then skyrocketed 1594.24% in 2024.
  • Year by year, Change in Accured Expenses stood at $4584.0 in 2021, then crashed by 40.99% to $2705.0 in 2022, then crashed by 71.76% to $764.0 in 2023, then soared by 1594.24% to $12944.0 in 2024, then plummeted by 36.33% to $8242.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for YJGJ at $8242.0 in Q4 2025, $406.0 in Q3 2025, and -$14185.0 in Q2 2025.